Skip to main content
Top
Published in: Endocrine 2/2016

01-11-2016 | Original Article

Serial post-surgical stimulated and unstimulated highly sensitive thyroglobulin measurements in low- and intermediate-risk papillary thyroid carcinoma patients not receiving radioactive iodine

Authors: Lawrence Kashat, Steven Orlov, David Orlov, Jasmeet Assi, Farnaz Salari, Paul G. Walfish

Published in: Endocrine | Issue 2/2016

Login to get access

Abstract

The purpose of this study was to determine the natural temporal trends of serial thyroglobulin (Tg) among low/intermediate-risk PTC patients not receiving radioactive iodine (RAI) using TSH-stimulated Tg (Stim-Tg) and unstimulated highly sensitive Tg (u-hsTg). We prospectively analyzed serial Stim-Tg measurements after total thyroidectomy ± therapeutic central neck dissection among 121 consecutive low/intermediate-risk PTC patients who did not receive RAI, of whom 104 also had serial u-hsTg measurements available. Median follow-up was 6.5 years with Stim-Tg measurements commencing 3 months after surgery and u-hsTg commencing 1.8 years after surgery (when the assay became available). TSH stimulation was performed with 9-day T3 withdrawal, 22-day T4 withdrawal, or using recombinant human TSH (rhTSH). To account for within-patient correlations of repeated Tg measurements, temporal trends in Stim-Tg and u-hsTg were assessed using Generalized Estimating Equations. Stim-Tg models were adjusted for the method of TSH stimulation, whereas the u-hsTg models were adjusted for concurrent TSH level. Linear regression modeling was used to assess the trend in serial Stim-Tg and u-hsTg measurements as a function time from time of surgery throughout the duration of follow-up. The main outcome measured was the change in u-hsTg and Stim-Tg measurements over time. A total of 337 Stim-Tg (2.8/patient) and 602 u-hsTg (5.8/patient) measurements were analyzed. Among the 337 Stim-Tg measurements, Stim-Tg was assessed using rhTSH in 202 (60 %), T4 withdrawal in 41 (12 %), and T3 withdrawal in 94 (28 %) measurements. The overall mean ± 1SD for Stim-Tg and u-hsTg measured was 1.0 ± 1.2 and 0.2 ± 0.1 μg/L, respectively. When adjusted for method of TSH stimulation, serial Stim-Tg measurements did not significantly change over time (all p = NS). The estimated changes in Stim-Tg per year for rhTSH, T4 withdrawal, and T3 withdrawal were 0.01, −0.08, and 0.04 μg/L, respectively. Upon exclusion of 73 patients with an initial undetectable Stim-Tg (n = 48), serial Stim-Tg measurements did not change significantly over time (all p = NS). For these patients, the estimated changes in Stim-Tg per year for rhTSH, T4 withdrawal, and T3 withdrawal were −0.09, −0.10, and 0.01 μg/L, respectively. Serial u-hsTg measurements did not significantly change over time after adjusting for TSH level (p = NS). The estimated change in u-hsTg per year was −0.003 μg/L. No patients had any clinical or imaging evidence of a recurrence during the duration of their follow-up. Among low/intermediate-risk PTC patients not treated with RAI, serial post-surgical Stim-Tg and u-hsTg measurements do not change significantly over a median follow-up of 6.5 years.
Literature
2.
go back to reference A.M. Sawka, K. Thephamongkhol, M. Brouwers, L. Thabane, G. Browman, H.C. Gerstein, Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 89(8), 3668–3676 (2004). doi:10.1210/jc.2003-031167 CrossRefPubMed A.M. Sawka, K. Thephamongkhol, M. Brouwers, L. Thabane, G. Browman, H.C. Gerstein, Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 89(8), 3668–3676 (2004). doi:10.​1210/​jc.​2003-031167 CrossRefPubMed
3.
go back to reference A. Vaisman, S. Orlov, J. Yip, C. Hu, T. Lim, M. Dowar, J.L. Freeman, P.G. Walfish, Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma. Head Neck 32(6), 689–698 (2010). doi:10.1002/hed.21371 PubMed A. Vaisman, S. Orlov, J. Yip, C. Hu, T. Lim, M. Dowar, J.L. Freeman, P.G. Walfish, Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma. Head Neck 32(6), 689–698 (2010). doi:10.​1002/​hed.​21371 PubMed
4.
go back to reference S. Orlov, F. Salari, L. Kashat, J.L. Freeman, A. Vescan, I.J. Witterick, P.G. Walfish, Post-operative stimulated thyroglobulin and neck ultrasound as personalized criteria for risk stratification and radioactive iodine selection in low- and intermediate-risk papillary thyroid cancer. Endocrine 50(1), 130–137 (2015). doi:10.1007/s12020-015-0575-0 CrossRefPubMed S. Orlov, F. Salari, L. Kashat, J.L. Freeman, A. Vescan, I.J. Witterick, P.G. Walfish, Post-operative stimulated thyroglobulin and neck ultrasound as personalized criteria for risk stratification and radioactive iodine selection in low- and intermediate-risk papillary thyroid cancer. Endocrine 50(1), 130–137 (2015). doi:10.​1007/​s12020-015-0575-0 CrossRefPubMed
5.
go back to reference R.P. Padovani, E. Robenshtok, M. Brokhin, R.M. Tuttle, Even without additional therapy, serum thyroglobulin concentrations often decline for years after total thyroidectomy and radioactive remnant ablation in patients with differentiated thyroid cancer. Thyroid 22(8), 778–783 (2012). doi:10.1089/thy.2011.0522 CrossRefPubMed R.P. Padovani, E. Robenshtok, M. Brokhin, R.M. Tuttle, Even without additional therapy, serum thyroglobulin concentrations often decline for years after total thyroidectomy and radioactive remnant ablation in patients with differentiated thyroid cancer. Thyroid 22(8), 778–783 (2012). doi:10.​1089/​thy.​2011.​0522 CrossRefPubMed
6.
go back to reference C. Durante, T. Montesano, M. Attard, M. Torlontano, F. Monzani, G. Costante, D. Meringolo, M. Ferdeghini, S. Tumino, L. Lamartina, A. Paciaroni, M. Massa, L. Giacomelli, G. Ronga, S. Filetti, Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement? J. Clin. Endocrinol. Metab. 97(8), 2748–2753 (2012). doi:10.1210/jc.2012-1123 CrossRefPubMed C. Durante, T. Montesano, M. Attard, M. Torlontano, F. Monzani, G. Costante, D. Meringolo, M. Ferdeghini, S. Tumino, L. Lamartina, A. Paciaroni, M. Massa, L. Giacomelli, G. Ronga, S. Filetti, Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement? J. Clin. Endocrinol. Metab. 97(8), 2748–2753 (2012). doi:10.​1210/​jc.​2012-1123 CrossRefPubMed
7.
go back to reference T.E. Angell, C.A. Spencer, B.D. Rubino, J.T. Nicoloff, J.S. LoPresti, In search of an unstimulated thyroglobulin baseline value in low-risk papillary thyroid carcinoma patients not receiving radioactive iodine ablation. Thyroid 24(7), 1127–1133 (2014). doi:10.1089/thy.2013.0691 CrossRefPubMed T.E. Angell, C.A. Spencer, B.D. Rubino, J.T. Nicoloff, J.S. LoPresti, In search of an unstimulated thyroglobulin baseline value in low-risk papillary thyroid carcinoma patients not receiving radioactive iodine ablation. Thyroid 24(7), 1127–1133 (2014). doi:10.​1089/​thy.​2013.​0691 CrossRefPubMed
8.
go back to reference C. Spencer, J. LoPresti, S. Fatemi, How sensitive (second-generation) thyroglobulin measurement is changing paradigms for monitoring patients with differentiated thyroid cancer, in the absence or presence of thyroglobulin autoantibodies. Curr. Opin. Endocrinol. Diabetes Obes. 21(5), 394–404 (2014). doi:10.1097/med.0000000000000092 CrossRefPubMedPubMedCentral C. Spencer, J. LoPresti, S. Fatemi, How sensitive (second-generation) thyroglobulin measurement is changing paradigms for monitoring patients with differentiated thyroid cancer, in the absence or presence of thyroglobulin autoantibodies. Curr. Opin. Endocrinol. Diabetes Obes. 21(5), 394–404 (2014). doi:10.​1097/​med.​0000000000000092​ CrossRefPubMedPubMedCentral
9.
go back to reference S. Orlov, D. Orlov, M. Shaytzag, M. Dowar, V. Tabatabaie, P. Dwek, J. Yip, C. Hu, J.L. Freeman, P.G. Walfish, Influence of age and primary tumor size on the risk for residual/recurrent well-differentiated thyroid carcinoma. Head Neck 31(6), 782–788 (2009). doi:10.1002/hed.21020 CrossRefPubMed S. Orlov, D. Orlov, M. Shaytzag, M. Dowar, V. Tabatabaie, P. Dwek, J. Yip, C. Hu, J.L. Freeman, P.G. Walfish, Influence of age and primary tumor size on the risk for residual/recurrent well-differentiated thyroid carcinoma. Head Neck 31(6), 782–788 (2009). doi:10.​1002/​hed.​21020 CrossRefPubMed
10.
go back to reference D.S. Cooper, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, S.J. Mandel, E.L. Mazzaferri, B. McIver, F. Pacini, M. Schlumberger, S.I. Sherman, D.L. Steward, R.M. Tuttle, Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19(11), 1167–1214 (2009). doi:10.1089/thy.2009.0110 CrossRefPubMed D.S. Cooper, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, S.J. Mandel, E.L. Mazzaferri, B. McIver, F. Pacini, M. Schlumberger, S.I. Sherman, D.L. Steward, R.M. Tuttle, Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19(11), 1167–1214 (2009). doi:10.​1089/​thy.​2009.​0110 CrossRefPubMed
11.
go back to reference A. Golger, T.R. Fridman, S. Eski, I.J. Witterick, J.L. Freeman, P.G. Walfish, Three-week thyroxine withdrawal thyroglobulin stimulation screening test to detect low-risk residual/recurrent well-differentiated thyroid carcinoma. J. Endocrinol. Invest. 26(10), 1023–1031 (2003)CrossRefPubMed A. Golger, T.R. Fridman, S. Eski, I.J. Witterick, J.L. Freeman, P.G. Walfish, Three-week thyroxine withdrawal thyroglobulin stimulation screening test to detect low-risk residual/recurrent well-differentiated thyroid carcinoma. J. Endocrinol. Invest. 26(10), 1023–1031 (2003)CrossRefPubMed
13.
go back to reference A.E. Hubbard, J. Ahern, N.L. Fleischer, M. Van der Laan, S.A. Lippman, N. Jewell, T. Bruckner, W.A. Satariano, To GEE or not to GEE: comparing population average and mixed models for estimating the associations between neighborhood risk factors and health. Epidemiology 21(4), 467–474 (2010). doi:10.1097/EDE.0b013e3181caeb90 CrossRefPubMed A.E. Hubbard, J. Ahern, N.L. Fleischer, M. Van der Laan, S.A. Lippman, N. Jewell, T. Bruckner, W.A. Satariano, To GEE or not to GEE: comparing population average and mixed models for estimating the associations between neighborhood risk factors and health. Epidemiology 21(4), 467–474 (2010). doi:10.​1097/​EDE.​0b013e3181caeb90​ CrossRefPubMed
14.
go back to reference C.A. Spencer, L.M. Bergoglio, M. Kazarosyan, S. Fatemi, J.S. LoPresti, Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. J. Clin. Endocrinol. Metab. 90(10), 5566–5575 (2005). doi:10.1210/jc.2005-0671 CrossRefPubMed C.A. Spencer, L.M. Bergoglio, M. Kazarosyan, S. Fatemi, J.S. LoPresti, Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. J. Clin. Endocrinol. Metab. 90(10), 5566–5575 (2005). doi:10.​1210/​jc.​2005-0671 CrossRefPubMed
15.
go back to reference A. Algeciras-Schimnich, M.A. Lasho, K.M. Ness, L.A. Cheryk, S.K. Grebe, The Roche Elecsys and Siemens-Centaur thyroglobulin autoantibody assays show comparable clinical performance to the recently unavailable Beckman-Coulter access thyroglobulin autoantibody assay in identifying samples with potentially false-low thyroglobulin measurements due to thyroglobulin autoantibody interference. Thyroid 21(7), 813–814 (2011). doi:10.1089/thy.2011.0158 CrossRefPubMedPubMedCentral A. Algeciras-Schimnich, M.A. Lasho, K.M. Ness, L.A. Cheryk, S.K. Grebe, The Roche Elecsys and Siemens-Centaur thyroglobulin autoantibody assays show comparable clinical performance to the recently unavailable Beckman-Coulter access thyroglobulin autoantibody assay in identifying samples with potentially false-low thyroglobulin measurements due to thyroglobulin autoantibody interference. Thyroid 21(7), 813–814 (2011). doi:10.​1089/​thy.​2011.​0158 CrossRefPubMedPubMedCentral
16.
go back to reference S. Edge, D.R. Byrd, C.C. Compton, A.G. Fritz, F.L. Greene (eds.), A.T.: AJCC Cancer Staging Manual, 7 ed (Springer, New York, 2010) S. Edge, D.R. Byrd, C.C. Compton, A.G. Fritz, F.L. Greene (eds.), A.T.: AJCC Cancer Staging Manual, 7 ed (Springer, New York, 2010)
17.
go back to reference C. Nascimento, I. Borget, F. Troalen, A. Al Ghuzlan, D. Deandreis, D. Hartl, J. Lumbroso, C.N. Chougnet, E. Baudin, M. Schlumberger, S. Leboulleux, Ultrasensitive serum thyroglobulin measurement is useful for the follow-up of patients treated with total thyroidectomy without radioactive iodine ablation. Eur. J. Endocrinol. 169(5), 689–693 (2013). doi:10.1530/eje-13-0386 CrossRefPubMed C. Nascimento, I. Borget, F. Troalen, A. Al Ghuzlan, D. Deandreis, D. Hartl, J. Lumbroso, C.N. Chougnet, E. Baudin, M. Schlumberger, S. Leboulleux, Ultrasensitive serum thyroglobulin measurement is useful for the follow-up of patients treated with total thyroidectomy without radioactive iodine ablation. Eur. J. Endocrinol. 169(5), 689–693 (2013). doi:10.​1530/​eje-13-0386 CrossRefPubMed
18.
go back to reference P.W. Rosario, G.F. Mourao, T.L. Siman, M.R. Calsolari, Serum thyroglobulin measured with a second-generation assay in patients undergoing total thyroidectomy without radioiodine remnant ablation: a prospective study. Thyroid 25(7), 769–775 (2015). doi:10.1089/thy.2014.0496 CrossRefPubMed P.W. Rosario, G.F. Mourao, T.L. Siman, M.R. Calsolari, Serum thyroglobulin measured with a second-generation assay in patients undergoing total thyroidectomy without radioiodine remnant ablation: a prospective study. Thyroid 25(7), 769–775 (2015). doi:10.​1089/​thy.​2014.​0496 CrossRefPubMed
19.
go back to reference P.W. Rosario, A.F. MineiroFilho, B.S. Prates, L.C. Silva, M.R. Calsolari, Postoperative stimulated thyroglobulin of less than 1 ng/ml as a criterion to spare low-risk patients with papillary thyroid cancer from radioactive iodine ablation. Thyroid 22(11), 1140–1143 (2012). doi:10.1089/thy.2012.0190 CrossRefPubMed P.W. Rosario, A.F. MineiroFilho, B.S. Prates, L.C. Silva, M.R. Calsolari, Postoperative stimulated thyroglobulin of less than 1 ng/ml as a criterion to spare low-risk patients with papillary thyroid cancer from radioactive iodine ablation. Thyroid 22(11), 1140–1143 (2012). doi:10.​1089/​thy.​2012.​0190 CrossRefPubMed
Metadata
Title
Serial post-surgical stimulated and unstimulated highly sensitive thyroglobulin measurements in low- and intermediate-risk papillary thyroid carcinoma patients not receiving radioactive iodine
Authors
Lawrence Kashat
Steven Orlov
David Orlov
Jasmeet Assi
Farnaz Salari
Paul G. Walfish
Publication date
01-11-2016
Publisher
Springer US
Published in
Endocrine / Issue 2/2016
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-016-0989-3

Other articles of this Issue 2/2016

Endocrine 2/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine